Status:
COMPLETED
A Controlled Clinical Trial Assessing the Efficacy of Vitamin B Prophylaxis in Attenuating Paclitaxel-induced Neuropathy and the Imperative Use of Gabapentin in Diabetic Ovarian Cancer Patients and the Potential Effect on Disease Response.
Lead Sponsor:
National Cancer Institute, Egypt
Conditions:
Peripheral Neuropathy, Chemotherapy-induced
Disease Management
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn if vitamin B prophylaxis is effective in attenuating chemotherapy-induced peripheral neuropathy in adult ovarian cancer patients. The main questions (primar...
Detailed Description
Patients received oral vitamin B complex as prophylaxis prior to starting their paclitaxel-based regimen and patients in the non-prophylaxis group received oral vitamin B complex upon developing chemo...
Eligibility Criteria
Inclusion
- Female patients with confirmed pathology of ovarian adenocarcinoma.
- Aged 18 years or older.
- Scheduled to receive a weekly paclitaxel-based chemotherapy regimen (80 mg/m²).
Exclusion
- Individuals under 18 years of age.
- Any patients with pre-existing peripheral neuropathy.
Key Trial Info
Start Date :
December 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2025
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT07191587
Start Date
December 1 2024
End Date
May 30 2025
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Cairo, Egypt, 11796